Relapsed Refractory Small Cell Lung Cancer clinical trials

Explore recruiting relapsed refractory small cell lung cancer clinical trials.

Recruiting relapsed refractory small cell lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Refractory Small Cell Lung Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination with Nivolumab in Participants with Relapsed/Refractory Small Cell Lung Cancer

Italy, Spain, Romania

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301).

Belgium, Denmark, Italy, Austria, Greece, Spain +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Relapsed Refractory Small Cell Lung Cancer trials by city

Relapsed Refractory Small Cell Lung Cancer in Toronto Relapsed Refractory Small Cell Lung Cancer in Vancouver Relapsed Refractory Small Cell Lung Cancer in Montreal Relapsed Refractory Small Cell Lung Cancer in Calgary Relapsed Refractory Small Cell Lung Cancer in Edmonton Relapsed Refractory Small Cell Lung Cancer in Ottawa Relapsed Refractory Small Cell Lung Cancer in Winnipeg Relapsed Refractory Small Cell Lung Cancer in Quebec City Relapsed Refractory Small Cell Lung Cancer in Hamilton Relapsed Refractory Small Cell Lung Cancer in Kitchener Relapsed Refractory Small Cell Lung Cancer in London Relapsed Refractory Small Cell Lung Cancer in Halifax Relapsed Refractory Small Cell Lung Cancer in New York Relapsed Refractory Small Cell Lung Cancer in Los Angeles Relapsed Refractory Small Cell Lung Cancer in Chicago Relapsed Refractory Small Cell Lung Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease